Drugs / CAN2109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06332430 | May 2024 → May 2025 overdue | cancer, lymphoma | Canwell Biotech Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-04-10 | CanWell Pharma Inc. | Regulatory CanWell Pharma’s First-in-Class innovative drug CAN2109 granted IND approval by China National Medical Products Administration (NMPA) canwellpharma.com ↗
CanWell Pharma announced that its First-in-Class innovative drug CAN2109, has been granted IND approval by the China National Medical Products Administration (NMPA). |
| 2023-11-16 | CanWell Pharma Inc. | Regulatory CanWell’s CAN2109 IND Granted Approval by US FDA canwellpharma.com ↗
CanWell Pharma announced that its First-in-Class innovative drug CAN2109, has been granted clinical approval by the US Food and Drug Administration (FDA) and it will soon conduct Phase I clinical trial for various solid tumors. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-04-10 | CanWell Pharma Inc. | CanWell Pharma’s First-in-Class innovative drug CAN2109 granted IND approval by China National Medical Products Administration (NMPA) canwellpharma.com ↗ |
| 2023-11-16 | CanWell Pharma Inc. | CanWell’s CAN2109 IND Granted Approval by US FDA canwellpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAN2109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06332430 ↗ |
| Route | Other | “Intratumoral CAN2109” NCT06332430 ↗ |